PPI in EMEA’s centralized switch
This article was originally published in The Tan Sheet
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use recommends selling the proton pump inhibitor Pantozol Control (pantoprazole 20 mg) OTC, according to a Feb. 19 release. The Nycomed GmbH product is the first PPI recommended for OTC status across Europe and is the second product recommended for OTC sale through Europe's centralized switch process. The first centrally switched nonprescription product in Europe is GlaxoSmithKline's weight-loss drug alli (1"The Tan Sheet" Oct. 27, 2008, p. 3)